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Abstract
Background: Volatile anesthetics increase levels of the neurotransmitter nitric oxide (NO) and the secondary
messenger molecule cyclic guanosine monophosphate (cGMP) in the brain. NO activates the enzyme guanylyl
cyclase (GC) to produce cGMP. We hypothesized that the NO-GC-cGMP pathway contributes to anesthesia-induced
unconsciousness.
Methods: Sevoflurane-induced loss and return of righting reflex (LORR and RORR, respectively) were studied in
wild-type mice (WT) and in mice congenitally deficient in the GC-1α subunit (GC-1−/− mice). Spatial distributions of
GC-1α and the GC-2α subunit in the brain were visualized by in situ hybridization. Brain cGMP levels were
measured in WT and GC-1−/− mice after inhaling oxygen with or without 1.2% sevoflurane for 20 min.
Results: Higher concentrations of sevoflurane were required to induce LORR in GC-1−/− mice than in WT mice (1.
5 ± 0.1 vs. 1.1 ± 0.2%, respectively, n = 14 and 14, P < 0.0001). Similarly, RORR occurred at higher concentrations of
sevoflurane in GC-1−/− mice than in WT mice (1.0 ± 0.1 vs. 0.8 ± 0.1%, respectively, n = 14 and 14, P < 0.0001).
Abundant GC-1α and GC-2α mRNA expression was detected in the cerebral cortex, medial habenula, hippocampus,
and cerebellum. Inhaling 1.2% sevoflurane for 20 min increased cGMP levels in the brains of WT mice from 2.6 ± 2.0
to 5.5 ± 3.7 pmol/mg protein (n = 13 and 10, respectively, P = 0.0355) but not in GC-1−/− mice.
Conclusion: Congenital deficiency of GC-1α abolished the ability of sevoflurane anesthesia to increase cGMP levels
in the whole brain, and increased the concentration of sevoflurane required to induce LORR. Impaired NO-cGMP
signaling raises the threshold for producing sevoflurane-induced unconsciousness in mice.
Keywords: Nitric oxide, Soluble guanylyl cyclase, Knock-out mouse, Volatile anesthetics, Sevoflurane, Righting reflex,
Cyclic guanosine monophosphate
Background
Intraoperative awareness is a major problem in anesthesia
[1], and it remains unknown why some patients are resist-
ant to anesthesia and more susceptible to experiencing
recall after an operation. People with red hair have been
reported to require higher doses of inhaled anesthetics
when compared to dark-haired people [2]. Red hair is
associated with mutations of the human melanocortin 1
receptor (MC1R), and deficiency of MC1R signaling is
characterized by reduced availability of NO [3].
Nitric oxide (NO) is a neurotransmitter in the central
nervous system that modulates signaling pathways rele-
vant to general anesthesia, including those involving
GABA [4], NMDA [5], and acetylcholine [6]. NO is
enzymatically generated by NO synthase (NOS) and can
signal through a multitude of downstream targets,
including guanylyl cyclase (GC). Upon activation by NO,
GC, a cytosolic heme protein consisting of an α1 or α2
subunit combined with a common β1 subunit, produces
the second messenger cyclic guanosine monophosphate
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(cGMP) [7]. Although GC-1 is the predominant isoform
throughout most organ systems including the cardiovas-
cular system, similar levels of GC-1 and GC-2 are
expressed in the brain [8]. In the central nervous system,
GC behaves like a neurotransmitter receptor character-
ized by rapid activation and slow desensitization [9]. The
ability of cGMP to control synaptic plasticity in the
mammalian brain is well documented [10]. Downstream
targets of cGMP include cGMP-dependent protein
kinases (PKG), phosphodiesterases, and cGMP-gated ion
channels.
Animal models are useful to explore the mechanisms
whereby the NO-cGMP system produces volatile
anesthesia’s effects on the brain. For example, halothane
[11–15], isoflurane [12, 16–18] and sevoflurane [12, 16]
each increase NO levels [11, 12, 16, 17] in the brain that
were abrogated by administration of NOS inhibitors [12,
17]. These anesthetics increase NO metabolites (nitrite
and nitrate) [18], and cGMP levels [13–15]. The γ-
aminobutyric acid type A (GABAA) receptor, an import-
ant molecular target for general anesthetics, modulates
NO-mediated cGMP synthesis in the rat cerebral cortex
in vivo [19]. A higher threshold for ethanol-induced loss
of righting reflex (LORR) was reported in a murine
model of PKG deficiency [20], suggesting that NO-
cGMP-PKG impacts ethanol-induced hypnosis. How-
ever, the precise role of NO-cGMP signaling in the hyp-
notic action of volatile anesthetics remains incompletely
understood.
In a previous study of cardiac ischemia-reperfusion in-
jury in mice deficient in GC-1α (GC-1−/−) [21], we noted
that higher concentrations of isoflurane were required to
anesthetize GC-1−/− mice than wild type (WT) mice
(unpublished observations). In the current report, we
sought to examine the impact of congenital GC-1 defi-
ciency on the sensitivity to sevoflurane-induced uncon-
sciousness, by measuring the LORR and return of the
righting reflex (RORR) of mice [22]. We hypothesized
that activation of GC-cGMP contributes to the hypnotic
effect of sevoflurane, and that GC-1−/− mice would be
less sensitive to sevoflurane-induced hypnosis.
Methods
Experimental animals
All experimental animal protocols were approved by the
Subcommittee on Research Animal Care at Massachusetts
General Hospital (The Institutional Animal Care and Use
Committee #2010 N000098), which conforms to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health [23], and all ex-
periments also conformed to Belgian and European law
on laboratory animal experimentation and were
approved by the Local Ethical Committee of Ghent
University (#99/26).
GC-1−/− mice with a targeted deletion of exon 6 of
GC-1α were generated on a 129S6 background (Taconic,
Hudson, NY), as previously described [24]. Body weight-
and age-matched WT 129S6 (Taconic, Hudson, NY) and
GC-1−/− mice were studied. The demographics of mice
(numbers, body weights, and ages) are presented in
Table 1 and were similar between WT and GC-1−/−
mice. A 12-h dark-light cycle beginning at 7:00 am
(lights on) was maintained in murine housing, with
water and a normal diet provided ad libitum. All experi-
ments were performed between 9:00 am and 3:00 pm.
Loss and return of the righting reflex
Anesthetic threshold was assessed behaviorally by meas-
uring the LORR and RORR. Male but not female GC-1
−/− mice have systemic hypertension [24], and female
hormones can modulate cognitive function [25] and
alter GC activity in the hypothalamus [26]. Therefore,
LORR and RORR were reported for each gender separ-
ately, as well as both genders combined. Unrestrained,
sevoflurane naive mice were placed in individual wire-
mesh cages rotating at 4 rpm in a 14 l glass chamber
(Chamber A) [22]. Ten liters per minute (l/min) of oxy-
gen was used to deliver sevoflurane (Piramal Critical
Care, Inc., Bethlehem, PA). Sevoflurane and oxygen con-
centrations inside Chamber A were measured at a gas
sampling flow rate of 200 ml/min, with an infrared gas
analyzer for sevoflurane and a paramagnetic oxygen
analyzer (Datascope Gas Module II, with anesthesia
monitor Passport 2, Mindray DS USA, Inc., Mahwah,
NJ). The tip of the gas sampling tube was secured at the
level of the median height of the mesh rotation cage
within Chamber A. Mice were habituated to the mesh
rotation cage while inhaling room air inside Chamber A,
rotating at 4 rpm for 2 h/day on 4 consecutive days prior
to the day of an anesthesia experiment. During experi-
ments, controlled concentrations of sevoflurane were
delivered to mice with a temperature-compensated
Table 1 Numbers, body weights and ages of mice used for the LORR and RORR experiments
Female WT Female GC-1−/− P Male WT Male GC-1−/− P
# of mice 8 8 6 6
BW (grams) 19.7 (18.6-20.7) 19.3 (18.8-19.9) 0.2656 24.7 (23.0-26.4) 24.7 (22.2-27.2) 0.8983
Age (weeks) 11.5 (10-12) 13.3 (12-14) 0.0002 12.1 (12-13) 12.6 (10-15) 0.5628
Data are presented as mean (95% CI)
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vaporizer (Baxter Drager Vapor 2000, Drägerwerk AG &
Co. KGaA, Lübeck, Germany) in 100% oxygen. Investi-
gators blinded to the genotype of the mice observed the
mice continuously, and recorded the timing of LORR
and RORR onset and the sevoflurane concentrations
required for LORR and RORR for each mouse.
Induction phase: Two mice, one WT and one GC-1−/−
mouse, were placed in separate mesh rotation cages, and
rotated inside Chamber A. On the day of the experi-
ment, mice were habituated for 30 min at 4 rpm inhal-
ing 10 l/min O2 without sevoflurane. Subsequently, a
high concentration of sevoflurane was delivered briefly
(2% for 30 s), and then the delivered sevoflurane concen-
tration was decreased to maintain a concentration of
0.6% in the chamber. The concentration in the chamber
was kept constant for 20 min, followed by stepwise in-
creases in the sevoflurane concentration by 0.1% incre-
ments, up to the highest concentration of 1.6% (Fig. 1).
Emergence phase: Thereafter, the sevoflurane concen-
tration was decreased from 1.6% to 1.0% (by 0.1% decre-
ments) until all mice regained the righting reflex (Fig. 1).
Each sevoflurane concentration was maintained for
20 min to allow the anesthetic dose to reach a steady
state in the brain.
We defined LORR as the inability of the mouse to
maintain itself on all four feet, and RORR as the time
when a mouse was able to right itself again for the first
time. If a mouse lost or regained its righting reflex dur-
ing the first 5 min after increasing or decreasing the
sevoflurane concentration, the sevoflurane concentration
required for LORR and RORR was calculated by (previ-
ous {sevo} + current {sevo}), divided by 2.
Since general anesthesia impairs thermoregulation, am-
bient temperature inside Chamber A was recorded every
30 s (Thermometer #90121, Springfield Precision, Wood-
Ridge NJ). A separate set of experiments was carried out
to evaluate the impact of prolonged exposure to sevoflur-
ane on core body temperature. Body temperature was
measured with a rectal probe at the end of the induction
period when mice were maximally anesthetized (220 min
after initial exposure to sevoflurane with the highest sevo-
flurane concentration of 1.6%). During this time, the am-
bient temperature inside Chamber A was maintained
between 27.5-29.0 °C using a heating lamp. Under the
same experimental conditions, we confirmed that the rec-
tal temperatures of WT and GC-1−/− mice were 39 ± 1.0
and 39 ± 0.8 °C, respectively (n = 7 each, p = 0.7769) at
0 min, and 37 ± 0.5 and 37 ± 0.7 °C (n = 7 each,
p = 0.4986) at 220 min.
In situ hybridization for GC-1α and GC-2α in mouse brain
Probes specific for the GC-1α and GC-2α isoforms were
cloned in vectors flanked by SP6 and T7 or T3 and T7
promoters, respectively. The GC-1α-specific probe was
290 base pair (bp) long, spanning a cDNA sequence
from exons 2-4, while the GC-2α-specific probe was
170 bp and contained the cDNA sequence from exon 8.
In vitro transcription of these probes using SP6, T3, or
T7 polymerase (Riboprobe, Promega) with digoxigenin-
labeled UTP was performed to generate labeled sense
and antisense transcripts. Non-incorporated nucleotides
were removed by gel filtration after in vitro transcrip-
tion. The specificity of the respective in situ probes was
tested on a dot blot using spotted dilutions of GC-1α,
GC-2α, and GC-1β cDNA. This blot showed that each
probe is isoform-specific. The GC-1α-specific probe was
290 bp long, spanning cDNA sequence from exons 2-4,
while the GC-2α-specific probe was 170 bp and con-
tained cDNA sequence from exon 8, and both regions
were chosen because of their dissimilarity between iso-
forms. The 290 bp GC-1α-specific cDNA fragment is
only 44% identical to GC-2α cDNA, and the GC-2α
probe is only 51% identical to GC-1α, both containing
many gaps in the sequence alignment.
Male WT mice were deeply anesthetized with tribro-
moethanol (intraperitoneal, 250 mg/kg), the chest was
opened, the inferior vena cava was cut, and mice were
perfused first with PBS and then with 4% paraformalde-
hyde (PFA) in PBS via infusion into the left ventricle.
Next, whole mouse brains were dissected and immedi-
ately fixed in 4% PFA in PBS for 12 h at 4 °C, and then
embedded in paraffin. Six-μM thick sections, cut with a
semi-automated microtome (Leica), were probed for the
presence of GC-1α and GC-2α mRNA using standard in
0 100 200 300
0.0
0.5
1.0
1.5
2.0
Time (min)
S
ev
of
lu
ra
ne
(%
)
LORR RORR
Fig. 1 Induction (loss of righting reflex, LORR) and emergence
(return of righting reflex, RORR) protocol for mice receiving
sevoflurane. During the induction phase, the chamber sevoflurane
concentration was increased to 2% for 30 s then rapidly decreased
to 0.6%. Next, the sevoflurane dose was increased stepwise (0.1%
every 20 min) up to 1.6%, then decreased to 1.0% by stepwise
decreases (0.1% every 20 min) until all mice regained the righting
reflex. The total duration of the experiment was 360 min, with an
induction phase of 220 min and an emergence phase of 140 min
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situ hybridization techniques. In brief, after deparaffina-
tion and dehydration sections were briefly post-fixed in
4% PFA and blocked in 0.1 M glycine. Permeabilization
with 10% proteinase K was followed by a second post-
fixation step, and prehybridization at 55 °C for 20 min in
hybridization solution containing 0.5 mg/ml tRNA,
0.5 mg/ml salmon sperm DNA, 1.25× SSC, 30% form-
amide, and 0.25× Denhardt’s solution. Consecutive sec-
tions were then incubated overnight at 55 °C with
digoxigenin-labeled antisense and sense probes, followed
by washing in 2xSSC and 1xSSC at 40 °C. After blocking
the section in sheep serum, the digoxigenin label was
detected using anti-digoxigenin-antibody coupled to
alkaline phosphatase (Roche). Finally, sections were de-
veloped in NBT/BCIP solution to visualize GC-1α- and
GC-2α-specific staining. Staining of sections with sense
probes was used as negative controls. Anatomic regional
localization of GC-1α- and GC-2α-positive cells were
confirmed by comparisons with the Allen mouse brain
atlas map of genes [27].
Brain cGMP measurements
Mice were habituated to being restrained in tapered
plastic cones (a 140 cm3 cone; Mouse Decapicone, DC-
M200, Braintree Scientific, Braintree, MA) for 20 min,
twice daily for three consecutive days prior to the day of
study. In order to obtain accurate brain cGMP analyses,
mice received an intraperitoneal injection of the
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX, 0.01 mcg/g, I-5879, Sigma-Aldrich, St. Louis,
MO) [28], right before going into a 2.5 l volume acrylic
anesthesia induction chamber (10″ × 4″ × 4″, Gas An-
esthetizing Box, AB-1, Braintree Scientific); Chamber B.
Mice breathed oxygen (5 l/min) without or with 1.2%
sevoflurane (Dräger Vapor 2000,Telford, PA) in Chamber
B, for 20 min. Rectal temperature was continuously moni-
tored (Mouse Rectal Temperature Probe, 382-0001-01,
Indus Instruments, Webster, TX, Traceable 2-Channel
Thermometer, VWR International, Radnor, PA) and main-
tained at 36.5-37.5 °C with a heating lamp. Concentrations
of sevoflurane and oxygen inside Chamber B were sam-
pled and continuously measured with a gas analyzer
(Datascope Gas Module II-Passport 2 system).
After 20 min of inhaling oxygen with/without sevoflur-
ane, mice were decapitated with a guillotine (Nemi Guil-
lotine, NS-80-1, Braintree Scientific) immediately after
removal from the chamber. To prevent degradation of
cGMP, dry ice was applied to the Nemi Guillotine and
plastic tubes, and a cold plate (Z176664, Sigma-Aldrich)
was used while dissecting the brain. Brain tissue was
snap frozen in liquid nitrogen and stored at −80 °C until
the analysis.
Brain cGMP levels were measured by blinded investi-
gators using an ELISA [29]. Briefly, harvested organs
were first powdered at −70 °C and subsequently homog-
enized in 1 ml ice-cold 100% ethanol. Extracts were cen-
trifuged at 14,000 g for 10 min at 37 °C. The
supernatant was transferred and the pellet was washed
once with 0.5 ml ice-cold 100% ethanol and centrifuged
at 14,000 g for 10 min at 37 °C. Next, the supernatant
was dried under a vacuum at 30 °C. The pellet was redis-
solved in protein buffer (20 mmol l−1 HEPES, 350 mmol
l−1 NaCl, 0.5 mmol l−1 EDTA, 20% glycerol, 0.5% Triton
X-100, EDTA-free protease inhibitor mix), centrifuged
for 10 min at 14,000 g at 37 °C, and the protein concen-
tration was measured using a BCA Protein Assay Kit
(Pierce). cGMP pellets were dissolved in EIA-buffer and
cGMP concentrations were measured using the acetyl-
ation protocol of the cyclic GMP EIA Kit (Cayman
Chemical). cGMP concentration is expressed as pico-
moles cGMP per milligram of brain protein. For all
cGMP experiments, mice were enrolled in small cohorts
(e.g. 2-4).
Data acquisition and statistical analysis
All data are presented as mean ± standard deviation. Sam-
ple sizes were obtained by statistical analysis software
G*Power (G*Power 3.1 [30], Heinrich-Heine-Universität
Düsseldorf, Düsseldorf, Germany). Randomization methods
were not used to assign mice to their experimental
condition.
Power analysis: Sample sizes for LORR/RORR experi-
ments in female mice were calculated based on our pre-
liminary data for the two-tailed t-test: effect size d = 1.6,
α error probability of 0.05 and power of 0.8. Sample size
for each female group (WT, GC-1−/−) was 8 mice.
Sample sizes for male mice were calculated based on the
female LORR (complete, %) data, for the two-tailed t-
test: effect size d = 2, α error probability of 0.05 and
power of 0.8. Sample size for each male group (WT,
GC-1−/−) was 6 mice. Sample sizes for the cGMP mea-
surements were initially calculated based on estimated
mean and standard deviation for the two-tailed t-test with
d = 1.2, α error probability of 0.05, and power of 0.8.
To achieve this level of power, sample size for each
group was required to be 12 mice. The statistical ana-
lyses for the hypothesis were conducted sequentially
using small cohorts of mice (e.g. n = 2-4). When the
sample size reached a total of n = 15 for the GC-1−/−
mice, an analysis was conducted that failed to reject the
null hypothesis and demonstrated a near zero effect size,
so the study was terminated without enrolling further
animals. No statistical adjustments were made to
account for this interim analysis.
All data were tested for normal distribution by the
Shapiro-Wilk normality test. To compare LORR and
RORR between WT and GC-1−/−, an un-paired inde-
pendent t-test was used for normally distributed data,
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and a Mann-Whitney U test was used for parameters
without a normal distribution. For comparisons of cu-
mulative probability for LORR and RORR curves, the
log rank Mantel-Cox test was used. For brain cGMP
measurements, parameters were logarithmically trans-
formed for analysis by ANOVA with Bonferroni correc-
tions, due to their abnormal distributions. P values <0.05
were considered significant. All statistical analysis was
performed using GraphPad Prism 6, version 5.01;
GraphPad Software, La Jolla, CA.
Results
The sevoflurane concentration required for LORR is higher
in GC-1−/− mice of both genders compared to WT mice
LORR and RORR are well-established endpoints to
determine anesthetic-induced unconsciousness and
recovery of consciousness in mice [22]. In female mice,
the mean sevoflurane concentration required to induce
LORR was 1.5% in GC-1−/− mice (95% confidence inter-
val; 95% CI: 1.4 to 1.6%, n = 8) and 1.1% in WT mice
(95% CI: 0.9 to 1.4%, n = 8, P = 0.0095. Figure 2a).
Similarly, in male mice, the mean sevoflurane concentra-
tion required to induce LORR was 1.6% in GC-1−/− mice
(95% CI: 1.5 to 1.6%, n = 6) and 1.1% in WT mice (95%
CI: 0.9 to 1.2%, n = 6; P = 0.0022. Figure 2b). When
combined, LORR occurred at higher mean sevoflurane
concentrations in GC-1−/− mice than in WT mice (1.5%,
95% CI: 1.4 to 1.6%, vs. 1.1%, 95% CI: 1.0 to 1.2%,
respectively, n = 14 and 14, P < 0.0001).
RORR occurred at a higher sevoflurane concentration in
GC-1−/− mice of both genders in comparison with WT mice
In female mice, the mean sevoflurane concentrations at
which RORR occurred were 1.0% in GC-1−/− mice (95%
CI: 0.9 to 1.1%, n = 8) and 0.9% in WT mice (95% CI:
0.8 to 0.9%, n = 8; P = 0.0451. Figure 3a). Similarly, in
male mice, the mean sevoflurane concentration required
to induce RORR was 1.1% in GC-1−/− mice (95% CI: 0.9
to 1.2%, n = 6) and 0.7% in WT mice (95% CI: 0.5 to
0.8%, n = 6; P = 0.0022. Figure 3b). When combined,
RORR occurred at higher sevoflurane concentrations in
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Fig. 2 Loss of righting reflex. GC-1−/− mice exhibit sevoflurane
hyposensitivity relative to wild-type mice (WT) in both females
(a) and males (b). Effects of genotype on LORR are significant in
both genders. Data presented as mean ± standard deviation. a: *
P = 0.0095, vs., WT mice. b: ** P = 0.0022, vs., WT mice
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Fig. 3 Return of righting reflex. GC-1−/− mice exhibit sevoflurane
hyposensitivity relative to wild-type mice (WT) in both females (a)
and males (b). Effects of genotype on RORR are significant in both
genders. Data presented as mean ± standard deviation. a: * P = 0.0451,
vs., WT mice. b: ** P = 0.0022, vs., WT mice
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GC-1−/− mice than in WT mice (1.0%, 95% CI: 0.9 to
1.1%, vs. 0.8%, 95% CI: 0.7 to 0.9%, respectively, n = 14
and 14, P < 0.0001).
Taken together, these results illustrate that GC-1−/−
mice of both sexes are more resistant to the hypnotic ef-
fects of sevoflurane than WT mice. Since the results
were similar in both sexes, subsequent in vitro brain GC
localization and cGMP measurements were obtained in
female mice only.
GC-1α and GC-2α are expressed in the cerebral cortex,
medial habenula, hippocampus and cerebellum of mice
In situ hybridization using GC-1α- and GC-2α-specific
antisense RNA probes revealed expression of both GC
isoforms throughout the murine brain. GC-1α and GC-2α
were expressed in cerebral cortex neurons, particularly in
layer II/III, and in the pyramidal layer of the piriform
cortex. In the third ventricle of the brain, GC mRNA was
detected in epithelial cells of the choroid plexus. In the
thalamus, GC-1α and GC-2α were readily detectable in
the medial habenulae. In the hippocampus, high levels of
GC expression were detected in the granular cell layer of
the dentate gyrus and in the pyramidal layer of the cornu
ammonis (CA). Staining for both isoforms was observed
in the Purkinje cell layer and Golgi cells of the granular
layer of the cerebellum, with lower levels detectable in
granule cells (Fig. 4).
Sevoflurane increases whole brain cGMP in WT but not in
GC-1−/− mice
To test whether GC-1 is involved in the sevoflurane-
induced cGMP increase in the brain, female WT and
GC-1−/− mice inhaled oxygen with or without 1.2% sevo-
flurane for 20 min. cGMP levels were measured in the
whole brain. In WT mice, inhalation of 1.2% sevoflurane
increased the levels of cGMP in the brain: average
cGMP levels were 2.6 pmol/mg protein (95% CI: 1.4 to
3.9, n = 13) and 5.5 pmol/mg protein (95% CI: 2.8 to 8.1,
P = 0.0355, vs. O2 alone, n = 10) in mice inhaling O2
alone and 1.2% sevoflurane in O2, respectively (Fig. 5).
In contrast, cGMP levels were similar in the brain of
GC-1−/− mice inhaling O2 alone (1.8 pmol/mg protein,
95% CI: 1.0 to 2.6, n = 8) or 1.2% sevoflurane in O2
(1.9 pmol/mg protein, 95% CI: 1.3 to 2.5, n = 7,
P = 0.9724, Fig. 5). These results provide evidence that
sevoflurane increases cGMP levels in the whole brain in
an GC-1-dependent manner.
Discussion
In this study, we report that a congenital deletion of
GC-1α increases the concentration of sevoflurane re-
quired to produce LORR in mice of both sexes. Expres-
sion of both GC-α isoforms (α1 and α2) was detected in
the cerebral cortex, medial habenulae, cerebellum and
hippocampus. During sevoflurane inhalation, levels of
cGMP in the whole brain were increased in WT mice,
but not in GC-1−/− mice. These results highlight a sig-
nificant role for the NO-GC-cGMP pathway in modulat-
ing sevoflurane-induced unconsciousness.
In the current study, LORR occurred at a higher con-
centration of sevoflurane in mice of both sexes with a
congenital GC deficiency as compared to WT mice, in-
dicating an important role for brain GC levels in loss of
consciousness and regaining wakefulness. One of the
major molecular targets for sevoflurane is thought to be
the GABAA receptor in the cortex [31], and the NO-
cGMP signaling system is present and active in cortical
GABA neurons. For example, cortical GABAA neurons
modulate NO-mediated cGMP synthesis [19], and the
heme-dependent GC stimulators BAY 41-2272 and YC-1
potentiate cGMP synthesis upon stimulation by NO-
donors in GABAergic and glutamatergic neurons in the
cortex [32]. Moreover, inhibition of the GABAA receptor
by the selective GABAA receptor antagonist bicuculline
increased cortical cGMP production in rats. This in-
creased cGMP production in response to bicuculline
may be indicative of a negative feedback mechanism to
further stimulate the GABA receptor [19]. The exact
mechanisms behind cGMP’s direct effects on the cortical
GABAA neurons remains to be elucidated.
We detected both GC-1α and GC-2α positive cells in
the cerebral cortex, medial habenulae, hippocampus,
cerebellum, and epithelial cells of the choroid plexus.
Our results are in accordance with the Allen mouse
brain atlas map of genes [27] and concur with previous
reports of the distribution of GC in the rat brain [33,
34]. cGMP binding sites were identified in regions over-
lapping with, or adjacent to, GC positive regions includ-
ing the habenulae, hippocampus, and cerebellum [35,
36], illustrating the presence of a fully functional cGMP
signaling system in areas of the central nervous system
that may regulate susceptibility to anesthesia. For ex-
ample, the strongest in situ hybridization signals for
both GC-1α and GC-2α were found in the medial habe-
nula, both in the current study as well as by others [36].
GC co-localizes with cGMP receptors in the medial
habenulae [35]. The medial habenulae have been re-
ported to regulate pain, anxiety, and sleep [37, 38], and
general anesthesia increased glucose uptake (an indicator
of the brain’s metabolic activity) in the habenular system
[39]. GC-cGMP signaling in the medial habenulae may
play an important role in modulating murine sensitivity
to anesthesia.
The role of NO-cGMP signaling in analgesia and loss
of consciousness induced by general anesthesia has been
a focus of intense investigation. Possible mechanisms
exerted by cGMP on brain function have been thor-
oughly reviewed, specifically in the context of neuronal
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long-term potentiation or depression in hippocampus,
amygdala and cerebellum to exert complex behaviors
[10]. cGMP increases NMDA receptor currents via
HCN channels contributing in both pre- [40] and post-
[41] synaptic plasticities. In vivo, the majority of studies
reported that pharmacological inhibition of NOS, either
all NOS enzymes non-selectively or NOS1 [22, 42–45],
of GC [46, 47], or of PKG-Iα [48] reduces MAC and/or
LORR in rodents. While these results differ from the
current observations, pharmacological inhibitors are
often nonspecific and may have “off-target” effects. It
has also been suggested that acute and chronic inhib-
ition of NO-cGMP signaling can produce distinct and
differing effects on anesthetic sensitivity [22, 44].
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Fig. 4 Localization of the expression of GCα isoforms in murine brain. In situ hybridization was performed on sections of adult mouse brain using
GC-1α- (a, d, g, j, m and p) and GC-2α- (b, e, h, k, n and q) specific antisense probes, as well as sense probes (c, f, i, l and o) as a negative control
(results obtained with the GC-2α sense probe were similar to those obtained with the GC-1α sense probe and are not shown here). Representative sections
of the cerebrum (coronal sections of the cerebral cortex: panels a-c, sagittal view of part of the limbic system: panels d-f, saggital view of hippocampus:
panels g-i) and the cerebellum (j-q) are shown. GC-1α and GC-2α were expressed in cerebral cortex neurons (layer II/III and the pyramidal layer of the
piriform cortex), third ventricle of the brain (epithelial cells of the choroid plexus), thalamus (medial habenulae), hippocampus (granular cell layer of the
dentate gyrus and in the pyramidal layer of the cornu ammonis), and cerebellum (Purkinje cell layer and Golgi cells of the granular layer, with lower levels
detectable in granule cells). GL: granular layer, ML: molecular layer, PCL: Purkinje cell layer, GN: Golgi neuron, PC: Purkinje cell, CA1-3: pyramidal layer of
regions 1-3 of the hippocampal cornu ammonis, DG: hippocampal dentate gyrus, CP: choroid plexus, HA: medial habenula, HI: hippocampus. Scale bars:
black: 200 μm, blue: 80 μm, white: 10 μm
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Therefore, a life-long congenital deficiency of NOS or
GC vs. acute pharmacological inhibition may have differ-
ent effects on anesthetic sensitivity.
The current study provides the first evidence that con-
genital GC-1α deficiency decreases anesthetic sensitivity
to sevoflurane in mice using proper genetic controls.
Two studies reported the impact of congenital NOS1
(neuronal NOS) deficiency on anesthetic sensitivity. Ichi-
nose and colleagues reported that NOS1 deficiency did
not affect minimum alveolar concentration (MAC) and
LORR to isoflurane anesthesia [22] whereas Engelhardt
and colleagues showed that NOS1 deficiency markedly
increased isoflurane MAC and tended to increase the re-
quired isoflurane concentration for LORR in mice [45],
in line with the current observations. The variable ef-
fects of NOS1 deficiency on anesthetic sensitivity may
be attributable to differences in the genetic background
of the mice that were studied, possibly associated with
the presence of additional genetic modifiers. It has been
reported that different mouse strains exhibit markedly
altered anesthetic sensitivity [49]. Both the GC-1−/− mice
and WT mice we studied were on the 129S6 back-
ground, while NOS1−/− and WT mice studied by Ichi-
nose et al. and Engelhardt and colleagues were on a
mixed B6/129 backgrounds. Also, it is important to note
that NO has targets beyond GC, and that differences ob-
served in NOS-deficient mice may be attributed to
NOS-dependent but GC-independent effects.
In humans, several families have been identified that
carry mutations in the gene that encodes GC-1α
(GUCY1A3) or the GC stabilizer (CCT7) [50, 51], result-
ing in a loss of GC activity. Subjects carrying these mu-
tations are highly susceptible to develop Moyamoya
disease [50], achalasia [50] and myocardial infarction
[51]. Anesthetic requirements for patients with GC
mutations, and the precise mechanisms for increased
anesthesia requirements of some patients remain
unclear. Our data suggest that impaired NO-cGMP
signaling, due to genetic mutations or other biochemical
abnormalities (e.g. decreased NO bioavailability), may
impact the doses of inhaled anesthetics required to in-
duce unconsciousness. For example, anesthetic require-
ments were reported to be increased in humans with red
hair [2], carrying mutations in the melanocortin-1 recep-
tor (MC1R) gene [2, 52]. These genetic variants were
previously reported to modulate κ-opioid analgesia in
humans [53]. More recently, however, results from a
matched-cohort study revealed that red-hair phenotype
does not appear to alter risk of intraoperative awareness
and postoperative recall, anesthetic requirements, or
recovery characteristics in surgical patients [54].
Since reduced endothelial NOS expression and de-
creased plasma levels of NO metabolites were described
in mice deficient in MC1R signaling [3], it remains con-
ceivable that downregulation of NO-cGMP signaling in-
duced by dysfunctional MC1R contributes to the
decreased sensitivity to inhaled anesthetics patients with
dysfunctional MC1R gene. Future investigations are re-
quired to further understand how NO-cGMP affects the
threshold of anesthesia.
In summary, we report that GC-1−/− mice require
higher doses of sevoflurane to achieve hypnosis com-
pared to WT mice. Although sevoflurane increased brain
cGMP levels in WT mice, this change was not observed
in GC-1−/− mice. These findings encourage additional
studies to elucidate how the NO-GC-cGMP pathway is
involved in anesthetic-induced hypnosis.
Conclusions
We report that congenital GC-1 deficiency decreases the
sensitivity to sevoflurane anesthesia in mice of both
sexes. The sevoflurane-induced increase in cGMP in the
WT brain was abrogated in mice congenitally lacking
GC-1. Our results suggest that patients with impaired
NO-cGMP signaling secondary to genetic mutations
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Fig. 5 Sevoflurane increases brain cGMP levels in WT mice but not in GC-1−/− mice. Brain cGMP levels in wild-type mice (WT) and GC-1−/− mice
inhaling 1.2% sevoflurane for 20 min. The control group (O2) breathed O2. Sevoflurane (Sevo) increased whole brain cGMP levels in WT mice, but
not in GC-1−/− mice. Data presented as mean ± standard deviation. Adjusted P values: * P = 0.0355 vs. WT O2 and P = 0.0062 vs. GC-1
−/− O2,
#
P = 0.0275 vs. WT Sevo, by one-way ANOVA. N = 13, 10, 8, 7 in WT O2, WT Sevo, GC-1
−/− O2, GC-1
−/− Sevo, respectively
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affecting the NO-cGMP system may require higher
anesthetic concentrations to induce unconsciousness.
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